TG Shifts Focus To MS After Pausing Oncology Programs, Ukoniq Withdrawal

Company Looks Ahead To Ublituximab PDUFA Date

 
• By Alaric DeArment
  
TG is shifting gears to focus on developing ublituximab in multiple sclerosis • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip